BioNTech forecasts lower 2025 revenue amid Pfizer write-downs and job cuts

BioNTech forecasts a revenue decline for 2025, expecting between 1.7 billion and 2.2 billion euros, down from 2.75 billion euros last year. This drop is due to Pfizer write-downs and stable vaccination rates. BioNTech also plans significant job cuts and new hires.

BioNTech, the German biotech company behind the COVID-19 vaccine, has warned of a significant decline in 2025 revenues, expecting them to range between 1.7 billion euros and 2.2 billion euros. This forecast is notably below the 2.75 billion euros reported last year and lower than analyst expectations of around 2.5 billion euros for 2025. 

The company attributed the expected revenue drop to stable vaccination rates and anticipated inventory write-downs at its collaboration partner Pfizer, which will negatively impact sales. Additionally, BioNTech revealed plans to reduce its workforce by 950 to 1,350 full-time positions by 2027, impacting its manufacturing and research operations in Europe and North America.

However, BioNTech also intends to add between 800 and 1,200 new roles, especially in its large-scale mRNA immunotherapy manufacturing facility in Mainz and through its acquisition of Biotheus. Despite these changes, the company expects its overall headcount to remain relatively stable in the next three years. Following the announcement, BioNTech's stock fell by 4.3%, reflecting investor concerns.

Copied